Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer

Urology

Volumn 73, Issue 4, 2009, Pages 697-705

  Simmons, Matthew N ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIANDROGEN; AZACITIDINE; BICLUTAMIDE; BMS 641988; CYPROTERONE ACETATE; DEGARELIX; DUTASTERIDE; ESTRAMUSTINE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 8; FLUTAMIDE; GONADORELIN AGONIST; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KETOCONAZOLE; MDV 13100; MESSENGER RNA; MZ J 7 138; NILUTAMIDE; PERIFOSINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; SMALL INTERFERING RNA; TESTOSTERONE; THYMOQUINONE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VN 124 1; VORINOSTAT; ZD 405449;

ANDROGEN DEPRIVATION THERAPY; ANTISENSE THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CASTRATION; CLINICAL TRIAL; DNA BINDING MOTIF; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; ORCHIECTOMY; OVERALL SURVIVAL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DOMAIN; REVIEW; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; CASTRATION; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 63149127344     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.09.040     Document Type: Review

References (53)

1. Huggins C. Endocrine control of prostatic cancer. Science 97 (1943) 541-544
2. Gittes R.F. Carcinoma of the prostate. N Engl J Med 324 (1991) 236-245
3. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
4. Schmitt B., Wilt T.J., Schellhammer P.F., et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57 (2001) 727-732
5. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5 (1982) 267-275
6. Shally A.V., Arimura A., Baba Y., et al. Isolation and properties of the FSH and LH-releasing hormone. Biochim Biophys Res Comm 43 (1971) 393-399
7. Peets E.A., Henson M.F., and Neri R. On the mechanism of the anti-androgenic action of flutamide (alpha-alpha-alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide) in the rat. Endocrinology 94 (1974) 532-540
8. Seguin C., Cusan L., Belanger A., et al. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol 21 (1981) 37-41
9. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
10. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
11. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
12. Lukka H., Waldron T., Klotz L., et al. Maximal androgen blockade for the treatment of metastatic prostate cancer-a systematic review. Curr Oncol 13 (2006) 81-93
13. Zhou Z.X., Lane M.V., Kemppainen J.A., et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9 (1995) 208-218
14. Gregory C.W., Johnson Jr. R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892-2898
15. Compagno D., Merle C., Morin A., et al. SIRNA-directed in Vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2 (2007) e1006
16. Hara T., Miyazaki H., Lee A., et al. Androgen receptor and invasion in prostate cancer. Cancer Res 68 (2008) 1128-1135
17. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
18. Montgomery R.B., Mostaghel E.A., Vessella R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68 (2008) 4447-4454
19. Page S.T., Lin D.W., Mostaghel E.A., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91 (2006) 3850-3856
20. Reddy G.P., Barrack E.R., Dou Q.P., et al. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98 (2006) 1408-1423
21. D'Antonio J. AR (androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)). Atlas Genet Cytogenet Oncol Haematol (2008). http://AtlasGeneticsOncology.org/Genes/ARID685chXq612.html January. Accessed on July 1, 2008
22. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332 (1995) 1393-1398
23. Bohl C.E., Gao W., Miller D.D., et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 102 (2005) 6201-6206
24. Wirth M.P., and Froschermaier S.E. The antiandrogen withdrawal syndrome. Urol Res 25 Suppl 2 (1997) S67-S71
25. Hirawat S., Budman D.R., and Kreis W. The androgen receptor: structure, mutations, and antiandrogens. Cancer Invest 21 (2003) 400-417
26. Brooke G.N., Parker M.G., and Bevan C.L. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27 (2007) 2941-2950
27. Klokk T.I., Kurys P., Elbi C., et al. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol 27 (2007) 1823-1843
28. Ettinger S.L., Sobel R., Whitmore T.G., et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64 (2004) 2212-2221
29. Culig Z., Hobisch A., Cronauer M.V., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
30. Zhang F., Lee J., Lu S., et al. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11 (2005) 4512-4520
31. Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in PTEN± mice. Genes Dev 20 (2006) 1569-1574
32. Kaarbo M., Klokk T.I., and Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29 (2007) 1227-1238
33. Singh A.P., Bafna S., Chaudhary K., et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 259 (2008) 28-38
34. Heinrich E., Schally A.V., Buchholz S., et al. Dose-dependent growth inhibition in Vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. [e-pub ahead of print]. Prostate 68 (2008) 1763-1772
35. Van Poppel H., Tombal B., de la Rosette J.J., et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 54 (2008) 805-815
36. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
37. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
38. Hsieh A.C., and Ryan C.J. Novel concepts in androgen receptor blockade. Cancer J 14 (2008) 11-14
39. Hwang D.J., Yang J., Xu H., et al. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem 14 (2006) 6525-6538
40. Kelly W.K. New drugs in the management of advanced prostate cancer. Cancer J 14 (2008) 10
41. Nickols N.G., and Dervan P.B. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A 104 (2007) 10418-10423
42. Mu Z., Hachem P., Hensley H., et al. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate 68 (2008) 599-609
43. Hadaschik B.A., and Gleave M.E. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25 (2007) 413-419
44. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
45. Sonpavde G., Aparicio A., Guttierez I., et al. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5 (2007) 457-459
46. Dasmahapatra G.P., Didolkar P., Alley M.C., et al. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 10 (2004) 5242-5252
47. Chee K.G., Longmate J., Quinn D.I., et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5 (2007) 433-437
48. Kaseb A.O., Chinnakannu K., Chen D., et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67 (2007) 7782-7788
49. Marrocco D.L., Tilley W.D., Bianco-Miotto T., et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6 (2007) 51-60
50. Maruyama-Takahashi K., Shimada N., Imada T., et al. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumour activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 68 (2008) 640-650
51. Ryan C.J., Harzstark A.H., Rosenberg J., et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 101 (2008) 436-439
52. Warren R., and Liu G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 17 (2008) 1237-1245
53. Sosman J.A., Puzanov I., and Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13 (2007) 764s-769s